Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Karen Mulder; Sheryl Koski; Andrew Scarfe; Quincy Chu; Karen King; Jennifer Spratlin

doi:10.18632/oncotarget.187

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Karen Mulder, Sheryl Koski, Andrew Scarfe, Quincy Chu, Karen King and Jennifer Spratlin _

PDF | HTML | How to cite

Oncotarget. 2010; 1:515-529. https://doi.org/10.18632/oncotarget.187

Metrics: PDF 5016 views | HTML 3894 views | ?

Abstract

Received: August 30, 2010, Accepted: October 15, 2010, Published: October 15, 2010

Advanced gastrointestinal (GI) malignancies are varied in presentation, prognosis, and treatment options. With the exception of resectable recurrent colorectal cancer, metastatic GI malignancies are incurable. Cytotoxic chemotherapies have been the mainstay of therapy for decades but limited extension of survival or clinical benefit has been achieved in non-colorectal GI cancers. There has been great interest in the incorporation of antiangiogenic strategies to improve outcomes for these patients. Clear benefits have been identified with bevacizumab and sorafenib in colorectal cancer and hepatocellular cancer, respectively; other GI tumor sites have lacked impressive results with antiangiogenic agents. In this review, we will present the benefits, or lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and explore some potential new therapeutic anti-angiogenesis options for these diseases.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 187

Publication Alerts

Reviews:

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Abstract